Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

C. Michael Gibson, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Gibson CM, Nafee T, Kerneis M. Conundrum of Using Real-World Observational Data to Inform Real-World Conclusions About Safety and Efficacy. J Am Coll Cardiol. 2018 Oct 09; 72(15):1801-1803. PMID: 30286923.
    Citations:    Fields:    
  2. Abnousi F, Sundaram V, Yong CM, Prats J, Deliargyris EN, Stone GW, Hamm CW, Steg PG, Gibson CM, White HD, Price MJ, Généreux P, Desai M, Yang L, Ding VY, Harrington RA, Bhatt DL, Mahaffey KW. Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. Am Heart J. 2017 Jun; 188:147-155. PMID: 28577670.
    Citations:    Fields:    Translation:Humans
  3. Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, Gibson CM, Ohman EM. Corrigendum to "A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease" [Am Heart J 181 (2016) 92-100]. Am Heart J. 2017 02; 184:156. PMID: 28224931.
    Citations:    Fields:    
  4. Gibson CM. Going Polymer Free and Dual Antiplatelet Free Earlier: The Coevolution of Stent and Pharmacotherapy. J Am Coll Cardiol. 2017 01 17; 69(2):172-175. PMID: 28081826.
    Citations:    Fields:    
  5. Gargiulo G, Windecker S, Vranckx P, Gibson CM, Mehran R, Valgimigli M. A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More? Circulation. 2016 Dec 06; 134(23):1881-1906. PMID: 27920074.
    Citations: 4     Fields:    Translation:HumansPHPublic Health
  6. Faggioni M, Farhan S, Baber U, Giustino G, Chieffo A, Colombo A, Henry T, Cohen D, Weisz G, Dangas G, Gibson C, Krucoff M, Steg PG, Kini A, Witzenbichler B, Pocock S, Mehran R. TCT-66 Effects of dual antiplatelet therapy cessation among patients with diabetes mellitus after PCI with DES. J Am Coll Cardiol. 2016 Nov 01; 68(18S):B27. PMID: 27970044.
    Citations:    
  7. Faggioni M, Chandrasekhar J, Baber U, Vogel B, Moliterno D, Henry T, Steg PG, Colombo A, Gibson C, Pocock S, Witzenbichler B, Chieffo A, Cohen D, Weisz G, Kini A, Dangas G, Krucoff M, Mehran R. TCT-219 Influence Of Anemia On Physician-Recommended DAPT Discontinuation After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016 Nov 01; 68(18S):B89. PMID: 27970393.
    Citations:    
  8. Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, Gibson CM, Ohman EM. A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. Am Heart J. 2016 Nov; 181:92-100. PMID: 27823698.
    Citations: 3     Fields:    Translation:HumansPHPublic Health
  9. Povsic TJ, Roe MT, Ohman EM, Steg PG, James S, Plotnikov A, Mundl H, Welsh R, Bode C, Gibson CM. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. Am Heart J. 2016 Apr; 174:120-8. PMID: 26995378.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  10. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox K. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015 Apr; 169(4):472-8.e5. PMID: 25819853.
    Citations: 18     Fields:    Translation:Humans
  11. Harrington RA, Popma CJ, Gibson CM. Advances in understanding percutaneous coronary intervention pharmacology: ischemia, bleeding, the ISAR research group, and a commitment to progress. Coron Artery Dis. 2014 Sep; 25(6):453-5. PMID: 25072657.
    Citations:    Fields:    Translation:Humans
  12. Gibson CM, Krucoff M, Kirtane AJ, Rao SV, Mackall JA, Matthews R, Saba S, Waksman R, Holmes D. Design and rationale of the ANALYZE ST study: a prospective, nonrandomized, multicenter ST monitoring study to detect acute coronary syndrome events in implantable cardioverter-defibrillator patients. Am Heart J. 2014 Oct; 168(4):424-429.e1. PMID: 25262250.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  13. Gibson MC, Krucoff M, Fischell D, Fischell TA, Keenan D, Abueg C, Patel C, Holmes D. Rationale and design of the AngeLmed for Early Recognition and Treatment of STEMI trial: a randomized, prospective clinical investigation. Am Heart J. 2014 Aug; 168(2):168-74. PMID: 25066555.
    Citations:    Fields:    Translation:HumansPHPublic Health
  14. Connelly NR, Malik A, Madabushi L, Gibson C. Use of ultrasound-guided cryotherapy for the management of chronic pain states. J Clin Anesth. 2013 Dec; 25(8):634-6. PMID: 23988804.
    Citations:    Fields:    Translation:Humans
  15. Terkelsen CJ, Pinto DS, Thiele H, Clemmensen P, Nikus K, Lassen JF, Hildick-Smith D, Christiansen EH, Aarøe J, Hansen HH, Stankovic G, Junker A, Sianos G, Olivecrona G, Bøtker HE, Gibson CM, Boersma E. 2012 ESC STEMI guidelines and reperfusion therapy: Evidence base ignored, threatening optimal patient management. Heart. 2013 Aug; 99(16):1154-6. PMID: 23781110.
    Citations: 4     Fields:    Translation:Humans
  16. Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW, Bhatt DL, Goto S, Cohen M, Mohanavelu S, Burton P, Stone G, Braunwald E. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol. 2013 Jul 23; 62(4):286-90. PMID: 23602776.
    Citations: 13     Fields:    Translation:Humans
  17. Celik T, Kaya MG, Akpek M, Yarlioglues M, Sarli B, Topsakal R, Gibson CM. Does Serum Bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI. Angiology. 2014 Mar; 65(3):198-204. PMID: 23378197.
    Citations: 5     Fields:    Translation:Humans
  18. Akpek M, Kaya MG, Lam YY, Sahin O, Elcik D, Celik T, Ergin A, Gibson CM. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012 Sep 01; 110(5):621-7. PMID: 22608360.
    Citations: 42     Fields:    Translation:HumansCells
  19. Pinto DS, Frederick PD, Chakrabarti AK, Kirtane AJ, Ullman E, Dejam A, Miller DP, Henry TD, Gibson CM. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation. 2011 Dec 06; 124(23):2512-21. PMID: 22064592.
    Citations: 16     Fields:    Translation:Humans
  20. Akpek M, Kaya MG, Uyarel H, Yarlioglues M, Kalay N, Gunebakmaz O, Dogdu O, Ardic I, Elcik D, Sahin O, Oguzhan A, Ergin A, Gibson CM. The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI. Atherosclerosis. 2011 Nov; 219(1):334-41. PMID: 21831375.
    Citations: 15     Fields:    Translation:Humans
  21. Cicek G, Uyarel H, Ergelen M, Ayhan E, Abanonu GB, Eren M, Gibson CM. Hemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. Coron Artery Dis. 2011 May; 22(3):131-7. PMID: 21394027.
    Citations: 9     Fields:    Translation:Humans
  22. Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, Plotnikov A, Sun X, Cook-Bruns N, Braunwald E. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J. 2011 May; 161(5):815-821.e6. PMID: 21570509.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  23. Gibson CM, Maehara A, Lansky AJ, Wohrle J, Stuckey T, Dave R, Cox D, Grines C, Dudek D, Steg G, Parise H, Wolff SD, Cristea E, Stone GW. Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. Am Heart J. 2011 Mar; 161(3):478-486.e7. PMID: 21392601.
    Citations: 7     Fields:    Translation:Humans
  24. Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation. 2010 Feb 16; 121(6):784-91. PMID: 20124127.
    Citations: 21     Fields:    Translation:HumansCells
  25. Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol. 2009 Dec 08; 54(24):2290-5. PMID: 19958964.
    Citations: 17     Fields:    Translation:Humans
  26. Gibson CM. Antiplatelet therapy: anti-ischemic benefits versus bleeding risk. J Interv Cardiol. 2008 Dec; 21 Suppl 1:S3-9. PMID: 19090934.
    Citations:    Fields:    Translation:Humans
  27. Gibson CM, Pride YB, Frederick PD, Pollack CV, Canto JG, Tiefenbrunn AJ, Weaver WD, Lambrew CT, French WJ, Peterson ED, Rogers WJ. Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J. 2008 Dec; 156(6):1035-44. PMID: 19032997.
    Citations: 42     Fields:    Translation:Humans
  28. Gibson CM, Pride YB, Aylward PE, Col JJ, Goodman SG, Gulba D, Bergovec M, Kunadian V, Zorkun C, Buros JL, Murphy SA, Antman EM. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. J Thromb Thrombolysis. 2009 Jan; 27(1):11-7. PMID: 18695943.
    Citations: 2     Fields:    Translation:Humans
  29. Gibson CM, Pride YB, Buros JL, Kunadian V, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, Braunwald E. Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy. Am J Cardiol. 2008 May 01; 101(9):1232-8. PMID: 18435949.
    Citations:    Fields:    Translation:Humans
  30. Gibson CM, Pride YB, Buros JL, Lord E, Shui A, Murphy SA, Pinto DS, Zimetbaum PJ, Sabatine MS, Cannon CP, Josephson ME. Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008 Feb 05; 51(5):546-51. PMID: 18237683.
    Citations: 4     Fields:    Translation:Humans
  31. Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman SG, Mahaffey KW, Cohen M, McCabe CH, Antman EM, Braunwald E. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J. 2007 Sep; 28(17):2077-86. PMID: 17600038.
    Citations: 23     Fields:    Translation:HumansPHPublic Health
  32. Gibson CM, Ciaglo LN, Southard MC, Takao S, Harrigan C, Lewis J, Filopei J, Lew M, Murphy SA, Buros J. Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review. J Thromb Thrombolysis. 2007 Apr; 23(2):135-45. PMID: 17221332.
    Citations: 8     Fields:    Translation:Humans
  33. Gibson CM, Ly HQ, Murphy SA, Ciaglo LN, Southard MC, Stein EB, Buros JL, Sabatine MS, Cannon CP. Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). Am J Cardiol. 2006 Sep 15; 98(6):761-3. PMID: 16950180.
    Citations: 2     Fields:    Translation:Humans
  34. Chang A, Gibson CM. Current Assessments of the Adequacy of Myocardial Perfusion During Acute MI. Curr Treat Options Cardiovasc Med. 2005 May; 7(1):25-34. PMID: 15913501.
    Citations:    
  35. Gibson CM, Kirtane AJ, Boundy K, Ly H, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. J Am Coll Cardiol. 2005 Feb 01; 45(3):357-62. PMID: 15680712.
    Citations: 4     Fields:    Translation:Humans
  36. Gibson CM. NRMI and current treatment patterns for ST-elevation myocardial infarction. Am Heart J. 2004 Nov; 148(5 Suppl):S29-33. PMID: 15514631.
    Citations: 17     Fields:    Translation:Humans
  37. Gibson CM, Karha J, Murphy SA, de Lemos JA, Morrow DA, Giugliano RP, Roe MT, Harrington RA, Cannon CP, Antman EM, Califf RM, Braunwald E. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 07; 43(7):1170-6. PMID: 15063425.
    Citations: 2     Fields:    Translation:Humans
  38. Guerra DR, Gibson CM. Door-to-Balloon Delays with PCI in Acute Myocardial Infarction. Curr Treat Options Cardiovasc Med. 2004 Feb; 6(1):69-77. PMID: 15023286.
    Citations: 1     
  39. Gibson CM, Karha J, Murphy SA, James D, Morrow DA, Cannon CP, Giugliano RP, Antman EM, Braunwald E. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003 Jul 02; 42(1):7-16. PMID: 12849652.
    Citations: 18     Fields:    Translation:Humans
  40. Gibson CM, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP, Roe MT, Harrington RA, Ohman EM, Antman EM. Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. J Thromb Thrombolysis. 2003 Jun; 15(3):189-96. PMID: 14739628.
    Citations: 7     Fields:    Translation:Humans
  41. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, Dauterman KW, Michaels A, Barron HV, Antman EM. Methodologic and clinical validation of the TIMI myocardial perfusion grade in acute myocardial infarction. J Thromb Thrombolysis. 2002 Dec; 14(3):233-7. PMID: 12913404.
    Citations: 5     Fields:    Translation:Humans
  42. Gibson CM, Dotani MI, Murphy SA, Marble SJ, Dauterman KW, Michaels AD, Dodge JT. Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Am Heart J. 2002 Jul; 144(1):130-5. PMID: 12094199.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  43. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002 Apr 23; 105(16):1909-13. PMID: 11997276.
    Citations: 48     Fields:    Translation:HumansCTClinical Trials
  44. Gibson CM, Chen M, Angeja BG, Murphy SA, Marble SJ, Barron HV, Cannon CP. Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery. J Thromb Thrombolysis. 2002 Feb; 13(1):9-12. PMID: 11994554.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  45. Gibson CM, Murphy SA, Marble SJ, Cohen DJ, Cohen EA, Lui HK, Young J, Kitt MM, Lorenz TJ, Tcheng JE. Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. Am Heart J. 2002 Jan; 143(1):106-10. PMID: 11773919.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  46. Gibson CM, Cohen DJ, Cohen EA, Lui HK, Murphy SA, Marble SJ, Kitt M, Lorenz T, Tcheng JE. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Am J Cardiol. 2001 Jun 01; 87(11):1293-5. PMID: 11377359.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  47. Gibson CM, Kirtane AJ, Murphy SA, Marble SJ, de Lemos JA, Antman EM, Braunwald E. Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction. Catheter Cardiovasc Interv. 2001 May; 53(1):6-11. PMID: 11329210.
    Citations: 1     Fields:    Translation:Humans
  48. Gibson CM, Murphy SA, Marble SJ, McCabe CH, Antman EM, Cannon CP, Braunwald E. Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. Am J Cardiol. 2001 Feb 15; 87(4):450-3, A6. PMID: 11179533.
    Citations: 1     Fields:    Translation:Humans
  49. Appleby MA, Michaels AD, Chen M, Michael CG. Importance of the TIMI frame count: implications for future trials. Curr Control Trials Cardiovasc Med. 2000; 1(1):31-34. PMID: 11714404.
    Citations: 1     
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Gibson's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (183)
Explore
_
Co-Authors (13)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.